Intellia Therapeutics, Inc. (NTLA)

From the record

Intellia Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Intellia Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $16 million in fiscal 2016 to $68 million in fiscal 2025, up 17% a year; it rose in 7 of 9 years; the deepest fall was 43% from fiscal 2020 to fiscal 2021; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Intellia Therapeutics, Inc. lost about 61 cents for every dollar of shareholders' money. Leverage: it owed about 20 cents per dollar of assets, and net share issuance: its share count grew 9.6% over the year (the filed statements).

From the record

Intellia Therapeutics, Inc.'s standing among 17 graded names in its industry family: revenue of $68 million in fiscal 2025 ranks in the top 32% by size; a net margin of -609.9% ranks in the bottom 32%; revenue growth of 9.1% a year over the last 3 filed years ranks in the top 34% (its annual reports).

From the record

Intellia Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Leonard, John M. (President and CEO, as filed), filing under that title since 2018-01-29, 8.8 years (top 29% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 4.7 years (top 39%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Intellia Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $155 million against no long-term debt tagged leaves 18.5% of its assets as net cash, top 36% of its family; cash from operations less capital spending is -585% of revenue (bottom 34%); research spending of 574.6% of revenue (top 28%) (its annual report).

From the record

Intellia Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 9.1% a year over the last three filed years against 17% over all 10, slowing (bottom 17% of its family); the newest year grew 16.9% (top 15%); research spending grew -2.5% a year (bottom 44%); capital spending grew -56.3% a year (bottom 17%) (its annual reports). Intellia Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Intellia Therapeutics, Inc.'s newest year against its own record: revenue of $68 million in fiscal 2025 came in 11% above the $61 million its prior three years' pace pointed to (top 30% of its family); net income of $413 million against a prior three-year average of $491 million (top 47%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 22%) (its annual reports).